Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. The company is headquartered in Lexington, Massachusetts.
| Revenue (TTM) | $9.44M |
| Gross Profit (TTM) | $-18.86M |
| EBITDA | $-32.73M |
| Operating Margin | -665.00% |
| Return on Equity | -2951.00% |
| Return on Assets | -67.20% |
| Revenue/Share (TTM) | $0.72 |
| Book Value | $0.42 |
| Price-to-Book | 4.39 |
| Price-to-Sales (TTM) | 2.46 |
| EV/Revenue | 2.172 |
| EV/EBITDA | 0.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -66.00% |
| Shares Outstanding | $39.98M |
| Float | $33.11M |
| % Insiders | 2.95% |
| % Institutions | 25.08% |
Volatility is currently contracting